Goldman Sachs’s MyoKardia, Inc. Common Stock MYOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-314,091
| Closed | -$42.8M | – | 5861 |
|
|
2020
Q3 | $42.8M | Sell |
314,091
-101,164
| -24% | -$10.8M | 0.01% | 1121 |
|
|
2020
Q2 | $40.1M | Buy |
415,255
+198,722
| +92% | +$16.6M | 0.01% | 1137 |
|
|
2020
Q1 | $10.2M | Buy |
216,533
+64,834
| +43% | +$4.15M | ﹤0.01% | 2072 |
|
|
2019
Q4 | $11.1M | Sell |
151,699
-44,175
| -23% | -$2.68M | ﹤0.01% | 2359 |
|
|
2019
Q3 | $10.2M | Buy |
195,874
+55,686
| +40% | +$2.96M | ﹤0.01% | 2317 |
|
|
2019
Q2 | $7.03M | Sell |
140,188
-120,186
| -46% | -$5.85M | ﹤0.01% | 2610 |
|
|
2019
Q1 | $13.5M | Buy |
260,374
+171,535
| +193% | +$7.9M | ﹤0.01% | 2186 |
|
|
2018
Q4 | $4.34M | Sell |
88,839
-21,312
| -19% | -$1.17M | ﹤0.01% | 3012 |
|
|
2018
Q3 | $7.18M | Buy |
110,151
+9,971
| +10% | +$586K | ﹤0.01% | 2705 |
|
|
2018
Q2 | $4.97M | Buy |
100,180
+1,821
| +2% | +$88.2K | ﹤0.01% | 2975 |
|
|
2018
Q1 | $4.8M | Buy |
98,359
+43,061
| +78% | +$2.24M | ﹤0.01% | 2925 |
|
|
2017
Q4 | $2.33M | Buy |
55,298
+3,292
| +6% | +$127K | ﹤0.01% | 3657 |
|
|
2017
Q3 | $2.23M | Buy |
52,006
+3,244
| +7% | +$103K | ﹤0.01% | 3883 |
|
|
2017
Q2 | $639K | Sell |
48,762
-7,638
| -14% | -$101K | ﹤0.01% | 4876 |
|
|
2017
Q1 | $742K | Buy |
56,400
+40,744
| +260% | +$522K | ﹤0.01% | 4659 |
|
|
2016
Q4 | $203K | Buy |
+15,656
| New | +$241K | ﹤0.01% | 5766 |
|
Goldman Sachs's MYOK Position: Q4 2020 in Review
Goldman Sachs sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 314,091 shares — an estimated $42.8M sold.
Goldman Sachs first reported a position in MYOK in Q4 2016 and held it in 16 quarters. The position peaked at $42.8M in Q3 2020. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.
- Goldman Sachs reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
- Goldman Sachs sold 314,091 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $42.8M.
- Goldman Sachs first reported a position in MyoKardia, Inc. Common Stock in Q4 2016 and held it in 16 quarters.
- Goldman Sachs's MyoKardia, Inc. Common Stock position peaked at $42.8M in Q3 2020.
- 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.
Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.